Pentostatin

"Pentostatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.

Descriptor ID	D015649
MeSH Number(s)	D03.383.742.680.350.200.700 D13.570.230.677 D13.570.685.350.200.700
Concept/Terms	Pentostatin Pentostatin Deoxycoformycin Co-Vidarabine 2'-Deoxycoformycin 2' Deoxycoformycin Nipent Nipent NSC-218321 NSC-218321 NSC 218321 NSC218321 CI-825 CI-825 CI 825 CI825

Below are MeSH descriptors whose meaning is more general than "Pentostatin".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyrimidines [D03.383.742]
Pyrimidine Nucleosides [D03.383.742.680]
Formycins [D03.383.742.680.350]
Coformycin [D03.383.742.680.350.200]
Pentostatin [D03.383.742.680.350.200.700]
Nucleic Acids, Nucleotides, and Nucleosides [D13]
Nucleosides [D13.570]
Deoxyribonucleosides [D13.570.230]
Pentostatin [D13.570.230.677]
Pyrimidine Nucleosides [D13.570.685]
Formycins [D13.570.685.350]
Coformycin [D13.570.685.350.200]
Pentostatin [D13.570.685.350.200.700]

Below are MeSH descriptors whose meaning is related to "Pentostatin".

Below are MeSH descriptors whose meaning is more specific than "Pentostatin".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Pentostatin" by people in this website by year, and whether "Pentostatin" was a major or minor topic of these publications.

Bar chart showing 10 publications over 8 distinct years, with a maximum of 2 publications in 2003 and 2006

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	1	1
2003	2	0	2
2006	0	2	2
2008	1	0	1
2009	0	1	1
2015	0	1	1
2019	0	1	1
2020	0	1	1

Below are the most recent publications written about "Pentostatin" by people in Profiles.

Braunstein Z, Mishra A, Staub A, Freud AG, Porcu P, Brammer JE. Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response. Br J Haematol. 2021 02; 192(3):484-493.

View in: PubMed
Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F. Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. Br J Haematol. 2019 05; 185(4):670-678.

View in: PubMed
Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol. 2015 Jun; 169(6):814-23.

View in: PubMed
Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10; 27(32):5425-30.

View in: PubMed
Sauter C, Lamanna N, Weiss MA. Pentostatin in chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2008 Sep; 4(9):1217-22.

View in: PubMed
Lamanna N, Weiss MA. Purine analogue-based chemotherapy regimens for second-line therapy in patients with chronic lymphocytic leukemia. Semin Hematol. 2006 Apr; 43(2 Suppl 2):S44-9.

View in: PubMed
Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz AD, Horgan D, Gencarelli A, Panageas KS, Scheinberg DA, Weiss MA. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006 Apr 01; 24(10):1575-81.

View in: PubMed
Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep. 2003 Sep-Oct; 10(5):1513-8.

View in: PubMed
Weiss MA, Maslak PG, Jurcic JG, Scheinberg DA, Aliff TB, Lamanna N, Frankel SR, Kossman SE, Horgan D. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol. 2003 Apr 01; 21(7):1278-84.

View in: PubMed
Parkinson SJ, Alekseev AE, Gomez LA, Wagner F, Terzic A, Waldman SA. Interruption of Escherichia coli heat-stable enterotoxin-induced guanylyl cyclase signaling and associated chloride current in human intestinal cells by 2-chloroadenosine. J Biol Chem. 1997 Jan 10; 272(2):754-8.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement